SQZ Biotechnologies Co Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021	Q2 FY2021 As of Jun 30, 2021	Q1 FY2021 As of Mar 31, 2021	Q4 FY2020 As of Dec 31, 2020	Q3 FY2020 As of Sep 30, 2020
Assets
Current assets:
Cash and cash equivalents
Marketable securities
Accounts receivable
Prepaid expenses and other current assets
Total current assets

Property and equipment, net
Restricted cash
Other assets
Deferred offering costs
Operating lease right-of-use assets
Total assets
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable
Accrued expenses
Accrued restructuring expenses
Deferred revenue
Current portion of operating lease liabilities
Total current liabilities
Deferred revenue, net of current portion
Operating lease liabilities, net of current portion
Other liabilities
Total liabilities
Convertible preferred stock (Series Seed, A, B, C and D), $0.001 par value; 0 and 16,670,802 shares authorized at December 31, 2020 and 2019, respectively; 0 and 13,869,027 shares issued and outstanding at December 31, 2020 and 2019), respectively; liquidation preference of $127,348 at December 31, 2019.
Stockholders’ equity:
Common stock, $0.001 par value; 200,000,000 shares authorized at June 30, 2023 and December 31, 2022; 29,491,125 shares issued and outstanding at June 30, 2023 and December 31, 2022.
Additional paid-in capital
Accumulated other comprehensive income
Accumulated deficit
Total stockholders’ equity

Total liabilities and stockholders’ equity

Comments